Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs

Monday, December 11, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 11, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, WallStEquities.com has issued free tailored Stock Review on PTN, ATOS, DBVT, and IDXX which is a click away at http://www.wallstequities.com/registration. Today's research on WallStEquities.com is concentrated on the Diagnostic Substances
industry, which develops and manufactures biological, chemical, and radioactive substances used in the process of detecting, diagnosing, and monitoring health conditions. Lined up for assessment this morning are: Palatin Technologies Inc. (NYSE AMER: PTN), Atossa Genetics Inc. (NASDAQ: ATOS), DBV Technologies S.A. (NASDAQ: DBVT), and IDEXX Laboratories Inc. (NASDAQ: IDXX). Wall St. Equities explores the latest technical developments on today's equity selection at:

http://www.wallstequities.com/registration

Palatin Technologies 

Cranbury, New Jersey-based Palatin Technologies Inc.'s stock finished last Friday's session 2.07% higher at $0.87. A total volume of 1.40 million shares was traded. The Company's shares have advanced 13.39% in the past month, 41.97% over the previous three months, and 72.86% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.19% and 70.52%, respectively. Additionally, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have a Relative Strength Index (RSI) of 49.24.

On November 21st, 2017, Palatin Technologies announced that it has entered into a collaboration and license agreement with Kwangdong Pharmaceutical Co., Ltd ("Kwangdong"), for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction indications in the Republic of Korea. Kwangdong, based in Seoul, is a leading Korean pharmaceutical company with annual sales of approximately $919 million in 2016. A new drug application is anticipated to be filed with the US Food and Drug Administration in the first quarter of calendar year 2018. Complimentary subscription to our free research report on PTN at:

http://www.wallstequities.com/registration/?symbol=PTN

Atossa Genetics 

On Friday, shares in Seattle, Washington headquartered Atossa Genetics Inc. ended the session 4.39% lower at $0.31. The stock recorded a trading volume of 843,107 shares. The Company's shares are trading 31.62% below their 50-day moving average. Moreover, shares of Atossa Genetics, which focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the US, have an RSI of 41.35.

On November 14th, 2017, Atossa Genetics announced its results for Q3 and nine months ended September 30th, 2017. For Q3 2017, total operating expenses were approximately $2.1 million, G&A expenses were approximately $1.3 million, and R&D expenses were approximately $0.7 million. For the nine months ended September 30th, 2017, total operating expenses were approximately $5.6 million, G&A expenses were approximately $3.5 million, and R&D expenses were approximately $2.1 million. Access the free research report on ATOS now by signing up at:

http://www.wallstequities.com/registration/?symbol=ATOS

DBV Technologies 

Bagneux, France-based DBV Technologies S.A.'s shares gained 1.08%, closing the session at $21.46 with a total trading volume of 181,233 shares. The stock is trading 31.42% below its 50-day moving average. Shares of the Company, which engages in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children, have an RSI of 28.04.

On November 20th, 2017, DBV Technologies announced positive topline results from the Phase-III REALISE (REAL Life Use and Safety of EPIT) trial. The REALISE double-blinded period compared the safety of treatment with Viaskin Peanut 250 µg versus placebo for six months. The REALISE trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events. Are you already registered with Wall St. Equities? Do so now for free, and get the report on DBVT at:

http://www.wallstequities.com/registration/?symbol=DBVT

IDEXX Laboratories 

Westbrook, Maine headquartered Last Friday at the close, shares in IDEXX Laboratories Inc. recorded a trading volume of 263,478 shares. The stock ended the session 0.49% higher at $160.57. The Company's shares have advanced 7.00% in the past month, 0.21% over the previous three months, and 36.92% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.15% and 1.48%, respectively. Furthermore, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 61.12. Aspiring Member, please take a moment to register below for your free research report on IDXX at:

http://www.wallstequities.com/registration/?symbol=IDXX

--

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@wallstequities.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store